Buscar
Congreso SOLACI
HomeCoronary diseaseDrug-eluting stents

Drug-eluting stents

Ver Categoría

Coronary disease

BIODEGRADE: Does Stent Design Affect Long-Term Clinical Results?

Recent studies have shown that drug-eluting stents with biodegradable polymer and ultrathin struts are safe and effective,...
solaci -
Ver más
Antiplatelet

Is Using Drug-Eluting Balloons and Single Antiplatlelet Therapy Safe for Patients at High Risk for Bleeding Who Undergo Percutaneous Coronary Intervention?

The safety and efficacy of drug-coated balloons (DCB) has been established for the treatment of in-stent restenosis...
solaci -
Ver más
Chronic Ischemic cardiopathy

Can Drug Coated Balloon Be a Valid Option for Small Vessels?

One of the challenges of percutaneous coronary interventions (PCI) are <2.5 mm vessels, since complications and restenosis...
solaci -
Ver más
Coronary disease

IN.PACT Study | Should We Start Using DCBs More Frequently in Cases of Femoropopliteal Disease?

With the new devices (drug-eluting balloons , drug-eluting stents , and atherotomes) percutaneous treatment is becoming the...
solaci -
Ver más
Acute coronary syndromes

Long-Term Evolution of Hybrid Coronary Revascularization

Currently, myocardial revascularization surgery (MRS) and percutaneous coronary intervention (PCI) are the available strategies for multivessel coronary...
solaci -
Ver más
Antiplatelet

Is it Possible to Reduce DAPT Time in Diabetic Patients?

Short-duration dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with DES is growing steadily, especially for...
solaci -
Ver más
Coronary disease

Left Main Coronary Artery PCI Using State-of-the-Art Zotarolimus-Eluting Stents

Percutaneous coronary intervention (PCI) to the left main coronary artery (LMCA) with drug-eluting stent implantation is currently...
solaci -
Ver más
Chronic Ischemic cardiopathy

Trans-Stent Gradient as a Predictor of Adverse Events at Followup

Stenting a coronary lesion should not present a drop in pressure when measuring the treated segment with...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Dr. Juan Manuel Pérez - 0
Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

Noticias Institucionales

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad